Sleep and Circadian Rhythm Assessments for Opioid Use Disorder
(MOUD Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must be stable on your medication for opioid use disorder (no dose change) for the past month to participate.
What data supports the effectiveness of the treatment Multiple Sleep Latency Test, Polysomnography, Post-Illumination Pupillary Response (PIPR) for opioid use disorder?
Research shows that sleep problems are common in people with opioid use disorder, and treatments like methadone and buprenorphine can affect sleep patterns. Monitoring sleep with tools like wireless EEGs has been found useful in understanding sleep issues during opioid withdrawal, which suggests that assessing sleep and circadian rhythms could help improve treatment outcomes for opioid use disorder.12345
Is the treatment for sleep and circadian rhythm assessments in opioid use disorder generally safe for humans?
The studies reviewed focus on sleep monitoring and treatments for opioid use disorder, but they do not provide specific safety data for the sleep and circadian rhythm assessments themselves. However, these assessments, like the Multiple Sleep Latency Test and Polysomnography, are commonly used in sleep studies and are generally considered safe for humans.12346
How does this treatment for opioid use disorder differ from other treatments?
This treatment is unique because it uses a wireless EEG monitor to objectively assess sleep patterns in patients with opioid use disorder, providing precise measurements of sleep disturbances during opioid withdrawal, which is not typically addressed by standard opioid treatments like methadone or buprenorphine.12347
What is the purpose of this trial?
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.
Research Team
Karen Cropsey, Psy.D.
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for adults over 18 who are on stable doses of FDA-approved medications for opioid use disorder, such as methadone, XR-NTX, or buprenorphine. Participants must have a positive drug screen if prescribed these medications but cannot be using illicit opioids or other drugs like stimulants and benzodiazepines.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MOUD therapy with methadone, buprenorphine, or extended-release naltrexone, and undergo assessments of ipRGC function, sleep, and circadian rhythms
Follow-up
Participants are monitored for relapse and treatment outcomes, including self-reported drug cravings and withdrawal symptoms
Exploratory Assessment
10-day assessment of daily sleep-wake behavior and opioid craving/withdrawal symptoms in participants' normal environment
Treatment Details
Interventions
- Multiple Sleep Latency Test
- Polysomnography
- Post-Illumination Pupillary Response (PIPR)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator